CSF Examination is the Next Step
When brain biopsy is contraindicated due to inability to safely discontinue anticoagulation, proceed directly to cerebrospinal fluid (CSF) examination with flow cytometry, MYD88 L265P mutation analysis, and IL-10 level measurement to support the diagnosis of primary CNS lymphoma. 1
Rationale for CSF-Based Diagnosis
The 2024 EHA-ESMO guidelines explicitly address this exact clinical scenario, stating: "When brain biopsy is contraindicated, CSF examination is a valid option" 1. This is a Level IV, Grade B recommendation that provides a clear pathway forward when tissue diagnosis cannot be safely obtained.
Why Brain Biopsy Cannot Be Performed
Your patient presents a genuine contraindication to stereotactic brain biopsy:
- Intracranial neurosurgery requires 5 days of DOAC discontinuation in patients without renal failure 2
- With four-vessel CAD and atrial fibrillation, this patient has very high thrombotic risk that makes prolonged anticoagulation interruption extremely dangerous
- The French perioperative hemostasis guidelines classify intracranial neurosurgery as "very high hemorrhagic risk" requiring the longest interruption windows 2
- Bridging with heparin is only recommended for "very thrombotic high-risk" patients, but even this may be insufficient for safe neurosurgery 2
Specific CSF Testing Protocol
Obtain CSF and order the following specific tests 1:
- Flow cytometry - improves diagnostic sensitivity beyond conventional cytology alone
- MYD88 L265P mutation analysis - highly specific for PCNSL
- IL-10 level measurement - elevated in lymphoma
- Conventional cytology - though it underestimates CSF involvement when used alone
- Physical-chemical analysis - may show increased leukocyte count and high protein concentration suggesting meningeal dissemination
Important Caveat About Corticosteroids
Do NOT start corticosteroids before obtaining CSF 1. Corticosteroid therapy causes tumor involution and can render both tissue and CSF samples non-diagnostic 3, 4. The guidelines explicitly state: "Corticosteroid therapy before tissue biopsy should be avoided whenever clinically possible" 1. This same principle applies to CSF examination.
If the patient is clinically deteriorating with increased intracranial pressure, you face a difficult choice, but CSF should still be obtained urgently before any steroid administration if at all possible.
Concurrent Staging Workup
While pursuing CSF diagnosis, simultaneously complete the staging evaluation 1:
- FDG-PET/CT to exclude systemic lymphoma (4-12% of presumed PCNSL cases have systemic disease)
- Ophthalmological examination to assess for vitreoretinal involvement
- Repeat brain MRI within 14 days before treatment initiation (PCNSL has >90% Ki-67 expression and grows rapidly)
This is critical because primary CNS lymphoma and secondary CNS lymphoma require different treatment protocols and have different prognoses 1.
If CSF is Non-Diagnostic
If CSF examination fails to establish the diagnosis and the patient remains clinically stable, consider:
- Multidisciplinary discussion involving neurosurgery, hematology/oncology, cardiology, and anesthesia to reassess biopsy risk-benefit
- Ophthalmological evaluation with vitreous sampling if any ocular involvement is suspected (vitreous humor can be analyzed with flow cytometry, MYD88 mutation, and IL-10 levels) 1
- Empiric treatment consideration only as a last resort in an 83-year-old with multiple comorbidities, though this is not guideline-recommended
Clinical Reality in an 83-Year-Old
Given the patient's age (83 years) and significant comorbidities (four-vessel CAD, AF requiring anticoagulation), treatment tolerance will be limited regardless. High-dose methotrexate-based regimens carry substantial toxicity in elderly patients. The diagnostic approach via CSF is both safer and provides sufficient information to guide treatment decisions in this high-risk population.
The CSF-based diagnostic pathway represents the evidence-based standard of care when tissue biopsy is genuinely contraindicated 1.